Industry News

INC Research Holdings, Inc., a leading, global Phase I to IV contract research organization, today announced that Chief Executive Officer Jamie Macdonald will transition his role as CEO of the Company effective Oct. 1, 2016, to INC Research’ s current President and COO Alistair Macdonald. Alistair Macdonald, who has served as INC’ s President and COO since January 2013 and held various other leadership roles at the Company since 2002, will become a member of..."/>
INC Research Announces Transition of CEO Role from Jamie Macdonald to COO Alistair Macdonald Effective Oct. 1, 2016
Invacare Corporation today announced upcoming changes to its board of directors. General James L. Jones, who joined the board in 2010, has decided to step down effective August 26, 2016, as a result of his increasing global responsibilities and travel for his other professional roles. In addition, after 30 years of board service, Michael F. Delaney has expressed his intent not to stand for re-election when his term expires at the company’ s 2017 annual meeting."/>
Invacare Corporation Announces Changes to Its Board of Directors
Teleflex Reports Second Quarter 2016 Results
Illumina, Inc. announced today that Philip W. Schiller has joined the company’ s Board of Directors. Schiller is currently Apple’ s Senior Vice President of Worldwide Marketing and is a member of Apple’ s executive team responsible for the company’ s product marketing, developer relations, business marketing, education marketing, international marketing and App Store programs. This Smart News Release features multimedia."/>
Illumina Names Philip W. Schiller to its Board of Directors
Alexion Reports Second Quarter 2016 Results
Invacare Corporation today announced its financial results for the second quarter and first six months ended June 30, 2016.. On July 2, 2015, the company divested its United States medical device rentals businesses for long-term care facilities, which were a part of the Institutional Products Group segment. The rentals businesses were not deemed discontinued operations for financial reporting purposes, and therefore are included in 2015 GAAP and adjusted..."/>
Invacare Corporation Announces Financial Results for the Second Quarter and First Six Months of 2016
Boston Scientific Corporation generated sales of $2.126 billion during the second quarter ended June 30, 2016, compared to the company's guidance range for the quarter of $2.010 to $2.060 billion. This represents growth of 15 percent on a reported basis and 16 percent on an operational basis, all compared to the prior year period. The company reported a GAAP loss of $207 million, or$ per share, compared to earnings of $0.08 a year ago, and..."/>
Boston Scientific Announces Results For Second Quarter 2016
Novocure announced today that the company will hold a research and development day for analysts and investors on Monday, Dec. 12, 2016, from 1 to 4 p.m. EST in New York City. During the event, we plan to provide analyses from completed clinical trials, including the full 695 patient dataset from the EF-14 trial in newly diagnosed glioblastoma, data from the PANOVA phase 2 pilot trial in advanced pancreatic cancer and data from the INNOVATE phase 2 pilot trial in..."/>
Novocure to Host Research and Development Day on Dec. 12, 2016
BioMarin Pharmaceutical reported on Wednesday that it has received US Food and Drug Administration acceptance for the review of the submission of a Biologics License Application for cerliponase alfa, an investigational therapy to treat children with CLN2 disease, a form of Batten disease. In conjunction with the US FDA filing, the Prescription Drug User Fee Act goal date for the decision is set for 27 January 2017, added the company."/>
BioMarin Pharmaceutical's cerliponase alfa BLA accepted by the US FDA for review for treating CLN2 disease
INC Research Reports Second Quarter 2016 Results
Mylan NV reported on Wednesday that it has received US Federal Trade Commission clearance for its proposed transaction to acquire Meda Aktiebolag. Meda's acquisition is subject to the Mylan's divestiture of certain products not significant to Mylan's earnings following the consummation of its recommended public offer to the shareholders of Meda to tender all their shares in Meda to Mylan. The FTC clearance reportedly represents the final regulatory..."/>
Mylan passes US FTC clearance for planned acquisition of Meda
Harvard Bioscience, Inc., a global developer, manufacturer and marketer of a broad range of solutions to advance life science, reported financial results for the three and six months ended June 30, 2016.. Revenues for the three and six months ended June 30, 2016 were $26.1 million and $53.1 million, respectively. Loss per diluted share, as measured under U.S. generally accepted accounting principles, for the three and six months ended June 30, 2016 was..."/>
Harvard Bioscience Reports Second Quarter 2016 Financial Results
Mylan NV is divesting two generic drugs to resolve concerns from U.S. regulators that its acquisition of Swedish specialty drugmaker Meda AB would have led to higher prices for the medicines. Mylan said it has received all required government approvals for the $7.2 billion deal. Mylan, which is based in the Netherlands and run from offices in Cecil, agreed to sell the rights and assets related to generic felbamate, a treatment for refractory epilepsy, to Alvogen Pharma for..."/>
Mylan to divest two generic drugs to win antitrust clearance for Meda acquisition [The Pittsburgh Tribune-Review]
MEDNAX, Inc., the national medical group specializing in neonatal and other pediatric services, anesthesia, maternal-fetal, radiology, pediatric cardiology and other physician and management services, today reported earnings of $0.89 per diluted share for the three months ended June 30, 2016. On a non-GAAP basis, MEDNAX reported Adjusted EPS of $1.03. For the 2016 second quarter compared to the prior year period, MEDNAX reported:."/>
MEDNAX Reports Second Quarter GAAP EPS of $0.89; Adjusted EPS of $1.03
ContraVir Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it will present at the 2016 Canaccord Genuity Growth Conference being held August 10- 11, 2016, in Boston, MA. James Sapirstein, chief executive officer of ContraVir, will provide an overview of the company's business during a live presentation and is available to meet with..."/>
ContraVir Pharmaceuticals to Present at the 2016 Canaccord Genuity Growth Conference
SciClone Pharmaceuticals, Inc. today announced that it plans to report financial results for the second quarter 2016 on Tuesday, August 9, 2016. SciClone will host a conference call and webcast to provide a business and product update at 4:30 pm ET that day. The call will be hosted by Friedhelm Blobel, Ph.D., President and CEO, and Wilson W. Cheung, Senior Vice President and CFO."/>
SciClone Pharmaceuticals To Report Second Quarter 2016 Financial Results On August 9, 2016
Integra LifeSciences Holdings Corporation today reported its financial results for the second quarter ending June 30, 2016.."/>
Integra LifeSciences Reports Second Quarter 2016 Financial Results
Digirad Corporation today reported its financial results for the second quarter and six months ended June 30, 2016.. Total revenues for the 2016 second quarter were $32.1 million, an increase of 106 percent compared to the prior year’ s second quarter revenues of $15.5 million."/>
Digirad Corporation Reports Financial Results for the Second Quarter and Six Months ended June 30, 2016
Acorda Therapeutics, Inc. today provided a financial and pipeline update for the second quarter ended June 30, 2016.."/>
Acorda Provides Financial and Pipeline Update for Second Quarter 2016
Thermo Fisher Scientific Inc., the world leader in serving science, today reported its financial results for the second quarter of 2016, ended July 2, 2016.. Revenue increased 6% to $4.54 billion. GAAP diluted earnings per share increased 2% to $1.30. Adjusted EPS grew 10% to $2.03. Strengthened leadership in analytical instruments by launching a suite of software and Cloud-based solutions for research and applied markets, and introducing new products to..."/>
Thermo Fisher Scientific Reports Second Quarter 2016 Results
United Therapeutics Corporation today announced its financial results for the second quarter ended June 30, 2016.. "We are pleased with our second quarter 2016 financial results as total revenues exceeded $400 million and earnings beat $200 million," said Martine Rothblatt, Ph.D., United Therapeutics' Chairman and Chief Executive Officer. "These financial results strengthen our ability to advance our..."/>
United Therapeutics Corporation Reports Second Quarter 2016 Financial Results
FedEx package containing a check for $3,000, which you're urged to deposit..."/>
R.I. Department of Labor warns of scam found on EmployRI job board [The Providence Journal, R.I.]

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Financials956 Articles
Information Technology897 Articles
Consumer Discretionary750 Articles
Industrials596 Articles
Health Care593 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.